Abstract
Antagonism of DA D2 receptors is thought to be the primary molecular mechanism for the efficacy of existing antipsychotic agents. This efficacy is believed to arise from blockade of DA D2 receptors in the mesolimbic and prefrontal brain regions. However blockade of DA D2 receptors in the striatum and caudate is thought to be responsible for the severe side effects associated with antipsychotic therapy including EPS and TD. Neurons that synthesize and release DA have DA autoreceptors on their presynpatic terminals and cell bodies. Stimulation of these autoreceptors by DA results in a negative feedback signal attenuating the synthesis and release of DA from these neurons. It has been hypothesized that partial agonists selective for DA autoreceptors could inhibit DA neurotransmission and therefore have antipsychotic efficacy. This review details the structure-activity relationships of DA partial agonists selective for DA D2 autoreceptors. Compounds having D2 and D3 affinity or D2 and 5-HT1A activity are also discussed. Compounds with the appropriate level of partial agonist activity were shown to have better efficacy/side effect profiles in primate models than standard DA D2 antagonists.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.